Bellicum Pharmaceuticals, Inc logo

Bellicum Pharmaceuticals, Inc Share Price (NASDAQ: BLCM)

▲

-0.07

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 4 Mar 2024

Check the interactive Bellicum Pharmaceuticals, Inc Stock chart to analyse performance

Bellicum Pharmaceuticals, Inc Key Stats

Check Bellicum Pharmaceuticals, Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.07475
Open
$0.0801
Market Capitalization
$778.3K
Today's Volume
$6.1K
Revenue TTM
$1.5M
EBITDA
$-23.8M
Earnings Per Share (EPS)
$-0.67
Profit Margin
0.0%
Quarterly Earnings Growth YOY
-0.93%
Return On Equity TTM
-148.5%

Global Institutional Holdings in Bellicum Pharmaceuticals, Inc

  • Name

    Holdings %

  • Ikarian Capital, LLC

    4.72%

  • Long Focus Capital Management, LLC

    3.45%

  • Baker Bros Advisors LP

    2.62%

  • BlackRock Inc

    0.80%

  • Geode Capital Management, LLC

    0.77%

  • Vanguard Group Inc

    0.70%

Analyst Recommendation on Bellicum Pharmaceuticals, Inc Stock

Rating
Trend

Sell

    0%Buy

    50%Hold

    50%Sell

Based on 6 Wall street analysts offering stock ratings for Bellicum Pharmaceuticals, Inc(by analysts ranked 0 to 5 stars)

About Bellicum Pharmaceuticals, Inc

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
Organization
Bellicum Pharmaceuticals, Inc
Employees
13
CEO
Mr. David M. Maggio
Industry
Health Technology

Important FAQs about investing in BLCM Stock from India :

What is Bellicum Pharmaceuticals, Inc share price today?

Bellicum Pharmaceuticals, Inc share price today is as on at the close of the market. Bellicum Pharmaceuticals, Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Bellicum Pharmaceuticals, Inc share?

Bellicum Pharmaceuticals, Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Bellicum Pharmaceuticals, Inc stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Bellicum Pharmaceuticals, Inc Stock (BLCM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Bellicum Pharmaceuticals, Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Bellicum Pharmaceuticals, Inc Shares .

What is the minimum amount required to buy Bellicum Pharmaceuticals, Inc Stock (BLCM) from India?

Indian investors can start investing in Bellicum Pharmaceuticals, Inc (BLCM) shares with as little as ₹88.3 or $1 (as of September 14, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹883.00 in Bellicum Pharmaceuticals, Inc stock (as per the Rupee-Dollar exchange rate as on September 14, 2025). Learn more about fractional shares .

What are the returns that Bellicum Pharmaceuticals, Inc has given to Indian investors in the last 5 years?

Bellicum Pharmaceuticals, Inc stock has given 0.0% share price returns and 20.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?